precisionbiosciences.com Open in urlscan Pro
104.154.250.30  Public Scan

Form analysis
1 forms found in the DOM

GET https://precisionbiosciences.com/

<form action="https://precisionbiosciences.com/" method="get">
  <div class="search-container-inner">
    <input type="search" class="search-field form-fluid no-livesearch" placeholder="Search…" value="" name="s" title="Search for:">
    <i class="fa fa-search3"></i>
  </div>
</form>

Text Content

Careers Contact Us
 * Who We Are
   * Who We Are
     * Our History
     * Mission & Values
   * Our Team
     * Leadership
     * Board of Directors
   * Careers
 * ARCUS Genome Editing
   * Scientific Publications
     * ARCUS Platform
     * CAR T Immunotherapy
     * In Vivo Gene Editing
 * Pipeline
   * CAR T Immunotherapy
   * In Vivo Gene Editing
   * Clinical Trials
   * Expanded Access
 * Investors
   * Events & Presentations
   * Press Releases
   * Corporate Deck
   * Stock Information
   * Analyst Coverage
   * SEC Filings
   * Corporate Governance
   * Investor FAQs
 * Partnering



Dedicated to improving life. Overcome cancer. Cure genetic disease.

CAR T IMMUNOTHERAPY

Novel allogeneic chimeric antigen receptor (CAR) T cell
therapies for treating cancer.

IN VIVO GENE EDITING

In vivo gene editing therapies to permanently
correct genetic diseases.


DEDICATED TO IMPROVING LIFE

--------------------------------------------------------------------------------



At Precision BioSciences we are ‘Dedicated to Improving Life’ and are using our
novel ARCUS genome editing technology to develop a new class of medicines
designed to overcome and potentially cure, hard-to-treat conditions including
cancer and genetic diseases.

Learn more about our history and mission ›




ARCUS GENOME EDITING

--------------------------------------------------------------------------------



ARCUS is a precise and versatile genome editing technology discovered and
developed by scientists at Precision BioSciences. ARCUS uses sequence-specific
DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or
repair DNA of living cells and tissues.

Learn more about ARCUS Genome Editing ›


RECENT NEWS

January 9, 2023

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES RECAPS 2022 ACCOMPLISHMENTS AND OUTLINES 2023 CORPORATE
PRIORITIES AND PLANNED PORTFOLIO MILESTONES

January 6, 2023

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES RECEIVES FAVORABLE TYPE C FEEDBACK FROM THE FDA ON THE
COMPANY’S CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) STRATEGIES FOR LATE-STAGE
DEVELOPMENT OF AZERCABTAGENE ZAPRELEUCEL, ITS LEAD ALLOGENEIC CAR T CLINICAL
CANDIDATE

December 10, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES PRESENTS ANALYSIS OF AZER-CEL, ALLOGENEIC CAR T PRODUCT
ATTRIBUTES RELATED TO IN VIVO PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL
OUTCOMES AT 2022 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

November 10, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES CHANGE TO ITS BOARD OF DIRECTORS

November 8, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

November 3, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES DATA PRESENTATION ON EFFECTIVE CELL DOSE AND
FUNCTIONAL ATTRIBUTES OF CD19 ALLOGENEIC CAR T, AZER-CEL, AT THE UPCOMING 2022
AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

November 2, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER
8, 2022

October 26, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES GRANT OF INDUCEMENT AWARD PURSUANT TO NASDAQ
LISTING RULE 5635(C)(4)

October 11, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT THE EUROPEAN SOCIETY OF GENE & CELL THERAPY
(ESGCT) 29TH CONGRESS

September 29, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PARTICIPATE IN UPCOMING JEFFERIES CELL & GENETIC
MEDICINE SUMMIT

September 7, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PARTICIPATE IN UPCOMING H.C. WAINWRIGHT 24TH ANNUAL
GLOBAL INVESTMENT CONFERENCE

September 2, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES SENIOR LEADERSHIP ORGANIZATIONAL CHANGES

August 8, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

August 1, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST
8, 2022

July 14, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES CLOSING OF UNDERWRITTEN OFFERING OF COMMON STOCK

July 14, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES $50 MILLION OFFERING OF COMMON STOCK

July 14, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES IN VIVO GENE EDITING COLLABORATION WITH NOVARTIS
TO DEVELOP POTENTIALLY CURATIVE TREATMENT FOR DISORDERS INCLUDING SICKLE CELL
DISEASE

June 8, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES PROVIDES UPDATE ON ALLOGENEIC CAR T PROGRAMS AND PATH
FORWARD WITH ITS LEAD PBCAR0191 CANDIDATE FOR CAR T RELAPSED PATIENT POPULATION

June 3, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PROVIDE AN UPDATE ON ITS ONGOING ALLOGENEIC CAR T
PROGRAMS VIA HOSTED VIRTUAL WEBCAST AND CONFERENCE CALL ON WEDNESDAY, JUNE 8,
2022

June 3, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PARTICIPATE IN UPCOMING JEFFERIES HEALTHCARE CONFERENCE

May 31, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS MELINDA BROWN TO BOARD OF DIRECTORS

May 23, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS JULI BLANCHE AS CHIEF PEOPLE OFFICER

May 18, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES PUBLICATION IN MOLECULAR THERAPY OF ARCUS® IN
VIVO GENE EDITING AS A PROMISING THERAPEUTIC APPROACH TO CURE CHRONIC HEPATITIS
B INFECTION

May 16, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES PRECLINICAL DATA SHOWCASING PREMIER IN VIVO GENE
EDITING CAPABILITIES AT AMERICAN SOCIETY OF GENE & CELL THERAPY ANNUAL MEETING

May 12, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING
RULE 5635(C)(4)

May 9, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

May 2, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT PRECLINICAL IN VIVO GENE EDITING RESEARCH AT
UPCOMING AMERICAN SOCIETY OF GENE & CELL THERAPY 25TH ANNUAL MEETING

May 2, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 9,
2022

March 15, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE

March 8, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT FOURTH QUARTER AND FISCAL YEAR 2021 RESULTS ON
MARCH 15, 2022

January 4, 2022

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTH CARE
CONFERENCE

December 21, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES COMPLETES SPIN-OUT OF ELO LIFE SYSTEMS

December 11, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS CLINICAL PROGRAM UPDATES FOR ITS ALLOGENEIC CAR T
PIPELINE

December 6, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO HOST VIRTUAL WEBCAST AND CONFERENCE CALL TO REVIEW
INTERIM PHASE 1/2A PBCAR0191 CAR T DATA AND PROVIDE CAR T PROGRAM UPDATES ON
SATURDAY, DECEMBER 11, 2021

December 3, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT PRECLINICAL GENE EDITING DATA ON ITS
ARCUS-BASED CHRONIC HEPATITIS B PROGRAM AT THE HEP DART 2021 CONFERENCE

November 10, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

November 9, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO HIGHLIGHT CAPABILITIES OF ARCUS GENE EDITING FOR
ALLOGENEIC CAR T CELL IMMUNOTHERAPIES AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER
36TH ANNUAL MEETING

November 8, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS SAM WADSWORTH, PH.D. AND SHARI LISA PIRÉ, J.D. TO
BOARD OF DIRECTORS

November 4, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES TWO ORAL PRESENTATIONS HIGHLIGHTING UPDATED
INTERIM DATA FROM LEAD PBCAR0191 CAR T IMMUNOTHERAPY FOR RELAPSED AND REFRACTORY
B-CELL MALIGNANCIES AT THE 63RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF
HEMATOLOGY

November 3, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT THIRD QUARTER 2021 FINANCIAL RESULTS ON NOVEMBER
10, 2021 AND PARTICIPATE IN THE STIFEL 2021 VIRTUAL HEALTHCARE CONFERENCE ON
NOVEMBER 16, 2021

October 21, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT THE JEFFERIES VIRTUAL GENE THERAPY/EDITING
SUMMIT ON WEDNESDAY, OCTOBER 27, 2021

October 8, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES STATEMENT ON SAFETY OF ITS ALLOGENEIC CAR T CELLS

September 27, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES GRANT OF INDUCEMENT AWARD FOR NEWLY APPOINTED
CHIEF EXECUTIVE OFFICER PURSUANT TO NASDAQ LISTING RULE 5635(C)(4)

September 27, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS MICHAEL AMOROSO CHIEF EXECUTIVE OFFICER

September 10, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT H.C. WAINWRIGHT 23RD ANNUAL GLOBAL
INVESTMENT CONFERENCE

September 9, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES AND IECURE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT TO
DEVELOP ARCUS-BASED GENE EDITING THERAPIES

September 9, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES OUTLINES CLINICAL DEVELOPMENT STRATEGY FOR IN VIVO GENE
EDITING PIPELINE

September 2, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES AND TIZIANA LIFE SCIENCES ANNOUNCE EXCLUSIVE LICENSE
AGREEMENT TO EVALUATE FORALUMAB, A NOVEL, FULLY HUMAN ANTI-CD3 MONOCLONAL
ANTIBODY, IN CONJUNCTION WITH ALLOGENEIC CAR T CANDIDATES FOR CANCER TREATMENT

August 25, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO HOST IN VIVO GENE EDITING R&D EVENT ON SEPTEMBER 9,
2021

August 12, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

August 5, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT SECOND QUARTER 2021 FINANCIAL RESULTS ON AUGUST
12, 2021

July 1, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES DOSES FIRST PATIENT IN PHASE 1 ALLOGENEIC CAR T CLINICAL
TRIAL OF PBCAR19B IMMUNE EVADING STEALTH CELL FOR RELAPSED/REFRACTORY
NON-HODGKIN LYMPHOMA

June 28, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES AND SPRINGWORKS THERAPEUTICS DOSE FIRST PATIENT IN
EXPANDED PHASE 1/2A CLINICAL TRIAL EVALUATING PBCAR269A WITH NIROGACESTAT IN
PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

June 4, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS PROGRESS ON TWO STRATEGIES DESIGNED TO OPTIMIZE
DURABILITY OF ALLOGENEIC CAR T THERAPY IN R/R NON-HODGKIN LYMPHOMA

June 1, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES NEW STUDY PUBLISHED IN NATURE COMMUNICATIONS
USING ENGINEERED ARCUS NUCLEASE TO TARGET MUTANT MITOCHONDRIAL DNA IN VIVO

May 27, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS ALEX KELLY AS CHIEF FINANCIAL OFFICER

May 26, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PARTICIPATE IN THE JEFFERIES VIRTUAL HEALTHCARE
CONFERENCE

May 19, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT DATA FROM ITS FIRST GENERATION CD19 ALLOGENEIC
CAR T PROGRAM IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AT THE 2021 AMERICAN
SOCIETY OF CLINICAL ONCOLOGY MEETING

May 13, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS FIRST QUARTER AND 2021 FINANCIAL RESULTS AND
PROVIDES BUSINESS UPDATE

May 11, 2021

--------------------------------------------------------------------------------


NEW PRECLINICAL DATA PRESENTED AT THE 2021 AMERICAN SOCIETY OF GENETIC & CELL
THERAPY ANNUAL MEETING HIGHLIGHTS PRECISION BIOSCIENCES’ ARCUS IN VIVO GENOME
EDITING

May 6, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT FIRST QUARTER 2021 FINANCIAL RESULTS ON MAY 13,
2021

May 3, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES PAPER PRESENTATION AT THE ASSOCIATION FOR
RESEARCH IN VISION AND OPHTHALMOLOGY 2021 ANNUAL MEETING

April 27, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES POSTER PRESENTATION AT THE UPCOMING AMERICAN
SOCIETY OF GENE & CELL THERAPY ANNUAL MEETING

April 15, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS RENOWNED HEMATOLOGIST ALAN LIST, M.D. AS CHIEF
MEDICAL OFFICER

April 15, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REACQUIRES GLOBAL RIGHTS TO ITS ALLOGENEIC CAR T PROGRAMS

April 12, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS STANLEY R. FRANKEL, M.D. TO BOARD OF DIRECTORS

April 9, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PARTICIPATE IN THE TRUIST SECURITIES 2021 LIFE SCIENCES
VIRTUAL SERIES

April 6, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES CEO TRANSITION PLAN

March 29, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PARTICIPATE IN THE GUGGENHEIM HEALTHCARE TALKS 2021
GENOMIC MEDICINES & RARE DISEASE DAY

March 18, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE

March 12, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL
RESULTS ON MARCH 18, 2021

March 2, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCES

February 19, 2021

--------------------------------------------------------------------------------


PRECISION ANNOUNCES 3-YEAR PRE-CLINICAL STUDY RESULTS SHOWING LONG-TERM
DURABILITY AND SAFETY OF ARCUS IN VIVO GENE EDITING TO CUT LDL CHOLESTEROL
LEVELS IN NONHUMAN PRIMATES

February 4, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT GUGGENHEIM HEALTHCARE TALKS 2021 ONCOLOGY
DAY

January 25, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION
COVERING PBCAR19B, A STEALTH CELL, CD19 ALLOGENEIC CAR T CANDIDATE FOR
NON-HODGKIN LYMPHOMA

January 19, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES FDA ACCEPTS IND FOR PBCAR19B, A NEXT-GENERATION,
STEALTH CELL, CD19 ALLOGENEIC CAR T CANDIDATE FOR NON-HODGKIN LYMPHOMA

January 7, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES CLOSING OF IN VIVO GENE EDITING COLLABORATION
AND LICENSE AGREEMENT WITH ELI LILLY AND COMPANY

January 4, 2021

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT THE ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

December 14, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES EXECUTIVE LEADERSHIP CHANGE

December 4, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS POSITIVE INTERIM RESULTS FROM PBCAR0191 PHASE 1/2A
TRIAL IN RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) AND R/R B-CELL
ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

November 24, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT THE PIPER SANDLER 32ND ANNUAL VIRTUAL
HEALTHCARE CONFERENCE

November 20, 2020

--------------------------------------------------------------------------------


LILLY AND PRECISION BIOSCIENCES ANNOUNCE GENOME EDITING RESEARCH COLLABORATION
AND LICENSE AGREEMENT

November 10, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

November 3, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT THIRD QUARTER 2020 FINANCIAL RESULTS ON NOVEMBER
10, 2020

October 15, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES U.S. PATENT TRIAL AND APPEAL BOARD UPHOLDS
ALLOGENEIC CAR T PATENTS

October 14, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES APPOINTS ALEX KELLY AS CHIEF CORPORATE AFFAIRS OFFICER

September 28, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN
OCTOBER

September 21, 2020

--------------------------------------------------------------------------------


ELO LIFE SYSTEMS APPOINTS FOOD AND BEVERAGE INDUSTRY TECHNOLOGY LEADER ALEC
HAYES AS VICE PRESIDENT OF TECHNOLOGY AND PRODUCTS

September 21, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES AND SPRINGWORKS THERAPEUTICS ANNOUNCE CLINICAL
COLLABORATION TO EVALUATE PBCAR269A IN COMBINATION WITH NIROGACESTAT IN PATIENTS
WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

September 17, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES AND SERVIER EXPAND CAR T ONCOLOGY DEVELOPMENT
COLLABORATION WITH FOUR NEW PROGRAMS TARGETING HEMATOLOGICAL AND SOLID TUMORS

September 9, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG
ADMINISTRATION FOR PBCAR269A, AN INVESTIGATIONAL ALLOGENEIC CAR T THERAPY FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA

September 2, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN
SEPTEMBER

August 19, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES RECEIVES FAST TRACK DISEASE DESIGNATION FROM U.S. FOOD AND
DRUG ADMINISTRATION FOR PBCAR0191 INVESTIGATIONAL ALLOGENEIC CAR T CELL THERAPY

August 13, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES
BUSINESS UPDATE

August 4, 2020

--------------------------------------------------------------------------------


ELO LIFE SYSTEMS ANNOUNCES STRATEGIC PARTNERSHIP WITH DOLE FOOD COMPANY WITH THE
GOAL OF SAVING THE CAVENDISH BANANA

August 3, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES TO REPORT SECOND QUARTER 2020 FINANCIAL RESULTS AND
PRESENT AT UPCOMING INVESTOR CONFERENCES

July 6, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES REGAINS RIGHTS TO IN VIVO HEPATITIS B VIRUS PROGRAM

June 8, 2020

--------------------------------------------------------------------------------


PRECISION BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2A CLINICAL
TRIAL OF PBCAR269A FOR MULTIPLE MYELOMA




AMONG US, WE HAVE THE DEEPEST AND STRONGEST SKILL SET WITHIN THE GENOME EDITING
INDUSTRY. WE CREDIT MUCH OF OUR SUCCESSES NOT ONLY TO OUR TECHNICAL KNOW-HOW,
BUT OUR COMMITMENT TO OUR TEAM AND OUR CULTURE.

Find your role at Precision today


CONTACT INFO

919.314.5512

Contact Us
Partner with Us
Career Opportunities

LEARN MORE

ARCUS Genome Editing
CAR T Immunotherapy
In Vivo Gene Editing
Pipeline
Clinical Trials

HEADING

Our Mission
Our Team

POLICIES

Terms of Use
Privacy Policy
Disclaimer
Cookie Policy

©2021 Precision BioSciences



This website uses cookies for analytics, personalized content and ads. By
clicking the “I Agree” button, you consent to our use of cookies. For more
information on our Cookie Policy, including an opt-out, please click the "Cookie
Policy" button.I AgreeCookie Policy